India's BDR Pharma seeks licence to sell version of Bristol-Myers Squibb cancer drug
MUMBAI, March 18
MUMBAI, March 18 (Reuters) - India's BDR Pharmaceuticals International Pvt Ltd has applied to the Indian patents office, seeking permission to sell a generic version of Bristol-Myers Squibb Co's cancer drug, dasatinib, through a so-called compulsory licence mechanism, a BDR executive said on Monday.
Under a global Trade-Related Aspects of Intellectual Property Rights (TRIPS) agreement, countries can issue compulsory licences for certain drugs that are deemed unaffordable to a large section of their populations.
Early this month, Bayer AG lost an appeal challenging the first-ever compulsory licence issued by India which allowed Natco Pharma to sell a version of the German drugmaker's cancer treatment Nexavar.
- Malaysia air probe finds scant evidence of attack: sources |
- Malaysia probes passenger backgrounds for clues on missing flight |
- Confrontation in Ukraine as diplomacy stalls |
- N.Korea using sophisticated means to avoid U.N. sanctions - U.N. report
- Exclusive: Chinese raw materials also found on U.S. B-1 bomber, F-16 jets